Oric Pharmaceuticals IncNASDAQ:ORIC
- LAST PRICE10.2500
- TODAY'S CHANGE (%)-0.4000 (-3.7559%)
- Bid / Lots10.0100/ 1
- Ask / Lots10.9100/ 10
- Open / Previous Close10.5300 / 10.6500
- Day Range
- 52 Week Range
- Volume271,313
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ORIC |
|---|---|---|
| 09:32 ET | 3554 | 10.64 |
| 09:34 ET | 3915 | 10.69 |
| 09:38 ET | 100 | 10.79 |
| 09:39 ET | 1700 | 10.765 |
| 09:41 ET | 280 | 10.84 |
| 09:43 ET | 430 | 10.81 |
| 09:50 ET | 1344 | 10.86 |
| 09:54 ET | 200 | 10.9 |
| 09:57 ET | 1199 | 10.79 |
| 10:01 ET | 200 | 10.735 |
| 10:03 ET | 500 | 10.7441 |
| 10:10 ET | 100 | 10.83 |
| 10:12 ET | 349 | 10.795 |
| 10:14 ET | 200 | 10.77 |
| 10:15 ET | 100 | 10.795 |
| 10:21 ET | 4427 | 10.615 |
| 10:24 ET | 3008 | 10.61 |
| 10:28 ET | 400 | 10.66 |
| 10:30 ET | 122 | 10.6639 |
| 10:32 ET | 367 | 10.684 |
| 10:33 ET | 200 | 10.69 |
| 10:35 ET | 400 | 10.7 |
| 10:37 ET | 613 | 10.69 |
| 10:39 ET | 300 | 10.66 |
| 10:42 ET | 600 | 10.66 |
| 10:44 ET | 100 | 10.69 |
| 10:48 ET | 1365 | 10.635 |
| 10:50 ET | 200 | 10.635 |
| 10:55 ET | 1312 | 10.59 |
| 10:57 ET | 3502 | 10.6 |
| 11:04 ET | 800 | 10.645 |
| 11:08 ET | 400 | 10.63 |
| 11:11 ET | 1400 | 10.61 |
| 11:13 ET | 223 | 10.64 |
| 11:15 ET | 600 | 10.64 |
| 11:18 ET | 700 | 10.62 |
| 11:20 ET | 695 | 10.62 |
| 11:22 ET | 1600 | 10.6 |
| 11:27 ET | 200 | 10.525 |
| 11:29 ET | 678 | 10.5 |
| 11:31 ET | 150 | 10.47 |
| 11:33 ET | 680 | 10.5 |
| 11:38 ET | 562 | 10.419448 |
| 11:40 ET | 230 | 10.4 |
| 11:42 ET | 1146 | 10.3713 |
| 11:44 ET | 300 | 10.335 |
| 11:54 ET | 261 | 10.395 |
| 12:00 ET | 100 | 10.4 |
| 12:02 ET | 1862 | 10.33 |
| 12:03 ET | 200 | 10.3262 |
| 12:05 ET | 3265 | 10.38 |
| 12:12 ET | 100 | 10.35 |
| 12:14 ET | 100 | 10.35 |
| 12:18 ET | 900 | 10.31 |
| 12:23 ET | 500 | 10.37 |
| 12:27 ET | 300 | 10.4 |
| 12:32 ET | 100 | 10.44 |
| 12:34 ET | 536 | 10.41 |
| 12:36 ET | 400 | 10.44 |
| 12:38 ET | 769 | 10.39 |
| 12:39 ET | 300 | 10.37 |
| 12:41 ET | 1715 | 10.33 |
| 12:43 ET | 612 | 10.36 |
| 12:45 ET | 200 | 10.355 |
| 12:54 ET | 1100 | 10.3168 |
| 12:56 ET | 680 | 10.28 |
| 01:12 ET | 1471 | 10.24 |
| 01:14 ET | 100 | 10.22 |
| 01:24 ET | 600 | 10.22 |
| 01:30 ET | 2500 | 10.17 |
| 01:37 ET | 100 | 10.165 |
| 01:39 ET | 7510 | 10.225 |
| 01:42 ET | 1695 | 10.16 |
| 01:46 ET | 499 | 10.1 |
| 01:48 ET | 900 | 10.09 |
| 01:50 ET | 834 | 10.12 |
| 01:51 ET | 1100 | 10.175 |
| 01:55 ET | 1676 | 10.185 |
| 01:57 ET | 260 | 10.19 |
| 02:00 ET | 918 | 10.1771 |
| 02:04 ET | 434 | 10.185 |
| 02:08 ET | 648 | 10.15 |
| 02:13 ET | 4400 | 10.13 |
| 02:24 ET | 3691 | 10.008763 |
| 02:26 ET | 300 | 9.99 |
| 02:27 ET | 313 | 10.01 |
| 02:29 ET | 500 | 10.025 |
| 02:33 ET | 100 | 10.025 |
| 02:36 ET | 332 | 10.05 |
| 02:38 ET | 100 | 10.08 |
| 02:40 ET | 3341 | 10.12 |
| 02:42 ET | 100 | 10.15 |
| 02:44 ET | 4883 | 10.19 |
| 02:45 ET | 404 | 10.185 |
| 02:47 ET | 10954 | 10.16 |
| 02:49 ET | 500 | 10.18 |
| 02:51 ET | 100 | 10.2 |
| 02:54 ET | 909 | 10.195 |
| 02:56 ET | 325 | 10.189 |
| 03:00 ET | 700 | 10.19 |
| 03:02 ET | 1207 | 10.18 |
| 03:03 ET | 600 | 10.18 |
| 03:05 ET | 522 | 10.22 |
| 03:07 ET | 447 | 10.225 |
| 03:09 ET | 100 | 10.225 |
| 03:12 ET | 100 | 10.225 |
| 03:14 ET | 967 | 10.175 |
| 03:20 ET | 319 | 10.1713 |
| 03:21 ET | 100 | 10.185 |
| 03:25 ET | 1200 | 10.22 |
| 03:27 ET | 400 | 10.215 |
| 03:30 ET | 1895 | 10.21 |
| 03:34 ET | 1168 | 10.18 |
| 03:36 ET | 280 | 10.2 |
| 03:41 ET | 200 | 10.22 |
| 03:43 ET | 2333 | 10.2003 |
| 03:45 ET | 100 | 10.195 |
| 03:50 ET | 682 | 10.2 |
| 03:52 ET | 3312 | 10.22 |
| 03:54 ET | 5186 | 10.28 |
| 03:56 ET | 2780 | 10.29 |
| 03:57 ET | 3284 | 10.29 |
| 03:59 ET | 68736 | 10.25 |
Sep 18, 2024
DJ Oric Pharmaceuticals Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 1:42PM ET on Wednesday Sep 18, 2024 by Dow Jones
1:42PM ET on Wednesday Sep 18, 2024 by Dow Jones
Sep 10, 2024
DJ Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush, from 9:08AM ET on Tuesday Sep 10, 2024 by Dow Jones
9:08AM ET on Tuesday Sep 10, 2024 by Dow Jones
Sep 6, 2024
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Friday Sep 06, 2024 by Dow Jones
4:30PM ET on Friday Sep 06, 2024 by Dow JonesDJ Oric Pharmaceuticals Initiated at Buy by Stifel, from 11:39AM ET on Friday Sep 06, 2024 by Dow Jones
11:39AM ET on Friday Sep 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Oric Pharmaceuticals Inc | 697.7M | -5.8x | --- |
Rapport Therapeutics Inc | 695.0M | -11.6x | --- |
ProKidney Corp | 692.3M | -3.3x | --- |
Savara Inc | 691.3M | -9.8x | --- |
Scholar Rock Holding Corp | 685.9M | -3.6x | --- |
MBX Biosciences Inc | 713.1M | -17.5x | --- |
Company Information
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Contact Information
- Headquarters
- 240 E. Grand Ave, 2nd FloorSOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-388-5600
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Richard Heyman
- President, Chief Executive Officer, Director
- Jacob Chacko
- Chief Financial Officer
- Dominic Piscitelli
- Chief Medical Officer
- Pratik Multani
- Independent Director
- Mardi Dier
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $697.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.11 |
EPS | $-1.76 |
Book Value | $4.08 |
P/E Ratio | -5.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
